Feb 28 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Announces management and business update
* Says J. Michael Pearson (L:PSON) to return as CEO following illness, effective
immediately
* Says Robert A. Ingram appointed chairman of the board
* Given timing of pearson's return, Valeant to reschedule call to discuss
preliminary Q4 2015 financial results
* Howard Schiller, valeant's interim chief executive officer, will transition
out of his current duties
* Says company has separated the roles of chairman and chief executive officer
* Says in the interim, the company is withdrawing its prior financial guidance
* Valeant pharmaceuticals-company will delay filing 2015 10-k pending
completion of review of certain accounting matters by ad hoc committee
* Confirms its wholly owned subsidiary, salix pharmaceuticals,received a notice
letter from actavis laboratories
* Notice stating U.S. FDA has received actavis' new drug application for
approval to market generic version of salix's xifaxan
* Expects to provide preliminary financial information for the fourth quarter
of 2015, and 2016 guidance, in the near term
* Howard Schiller,interim CEO, will transition out of his current duties but
will continue as a member of board
* Source text for Eikon ID:nPn903K48